Prophylactic antithrombotic therapy with stanozolol in patients with familial antithrombin III deficiency.
Three patients with familial antithrombin III deficiency underwent a trial of prophylactic antithrombotic therapy with stanozolol. An increase in plasma fibrinolytic activity and antithrombin III was seen. Acute venous thrombosis occurred in two patients; in the first patient thrombosis was precipitated by venography but in the second no precipitating factor was found. Our experience suggests that stanozolol is not a suitable prophylactic agent in patients with familial antithrombin III deficiency.
D000990:Antithrombin III / Q000032:analysis; D020152:Antithrombin III Deficiency; D001780:Blood Coagulation Tests; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D013197:Stanozolol / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control*
D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D013197:Stanozolol; D000990:Antithrombin III; D010958:Plasminogen; D002784:Cholesterol